Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden

Table 3 Association of angiogenesis inhibitor concentrations with plaque burden measured as total percent area stenosis

Factor (median [IQR])	Q1	Q2	Q3	Q4	P value
	2.16–3.78 %	3.86–4.95 %	4.96–6.37 %	6.39–13.2 %	P value
	n = 31	n = 30	n = 31	n = 30
Endostatin (ng/mL)	136.75 [83.51, 198.57]	134.87 [103.91, 191.11]	109.08 [83.17, 184.55]	118.38 [92.03, 150.14]	0.50
ADMA (μmol/L)	0.47 [0.40, 0.54]	0.43 [0.40, 0.51]	0.47 [0.41, 0.50]	0.48 [0.44, 0.56]	0.57
Thrombospondin-2 (pg/mL)	20,900.0 [14,800.0, 26,500.0]	21,000.0 [15,400.0, 33,000.0]	19,100.0 [15,200.0, 26,300.0]	26,000.0 [16,450.0, 33,900.0]	0.45
Endoglin (ng/mL), mean ± SD	4.43 ± 1.49	4.50 ± 1.08	3.91 ± 0.84	4.47 ± 1.23	0.18
Angiopoietin-2 (ng/mL)	2.08 [1.50, 3.11]	2.75 [1.51, 4.48]	2.45 [1.47, 4.86]	2.23 [1.71, 4.44]	0.79

Quartiles of plaque burden and distribution of mean or median values for endostatin (n = 115), thrombospondin-2 (n = 109), endoglin (n = 116), angiopoietin-2 (n = 108), and ADMA (asymmetric dimethyl arginine, n = 110) concentrations

ISSN: 1755-1536